Cloud compliance solutions for every stage of your journey
Where is your company in its journey?
Getting Started
You have to know where you are to know where you are going. We can help identify gaps, minimize risk, and fast-track getting where you want to be.
Getting Better
We can help you maximize the return on your technology investments, increase your cloud compliance maturity, and speed up GxP projects.
Getting Ahead
We can automate your GxP processes to increase efficiency and execute pilot programs using AI or ML to empower data-driven decisions.
How we can help:
- Provide regulatory training and guidance to improve internal know-how
- Establish quality and compliance best practices to minimize risk
- Ensure compliance and audit readiness to pass regulatory audits and speed time to market
- Define a compliant, IT roadmap based on regulatory milestones to maximize ROI
How we can help:
- Provide a free assessment to identify compliance and technology improvements
- Optimize technology to harmonize GxP and non-GxP functionality to save money and minimize system duplication
- Maintain continuous compliance of your GxP tech stack to decrease internal validation workload and increase team capacity
How we can help:
- Digitize and automate compliant processes and workflows to work faster and minimize human errors
- Extract more value from your data to activate new business models
- Empower data-driven decisions with AI and ML to innovate faster
- Scale new, agile business capabilities
Case Study
USDM helped a pre-commercial biotech establish a risk-based, phase-appropriate, CSV program and validated various application in less than 6 weeks to meet their FDA submission deadline.
Case Study
Learn how USDM accelerated the digital transformation of a large medical device manufacturer that resulted in an 85% reduction in licensing fees by optimizing GxP functionality.
Case Study
Learn how USDM helped a Top 5 global pharma company create a validated AI framework for Microsoft Azure to use AI chatbots to deliver GxP content at their clinical sites.